Latest Conference Articles

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

The addition of Optune to chemotherapy and/or bevacizumab improved survival in patients with recurrent glioblastoma multiforme.

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

Long-term data continue to show sustained improvements in overall survival with nivolumab alone or in combination with ipilimumab as a frontline treatment for patients with advanced melanoma.

With the FDA approval of the first oncolytic immunotherapy-talimogene laherparepvec (T-VEC; Imlygic)-the stage has been set for increased research into these agents.

Michael Krauthammer, MD, PhD, Associate Professor of Pathology, Yale School of Medicine, discusses the role of NF1 mutation in melanoma.

There were few differences in quality of life, global health, and symptom burden between patients with melanoma who were treated with nivolumab plus ipilimumab or either agent alone.

Predictive genetic signatures and novel combination strategies may be the key to improving the often dramatic responses seen with immune checkpoint inhibitors.

Sancy Leachman, MD,PhD, Professor and Chair, Department of Dermatology Director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses a new tool that oncologists can use with patients to identify melanoma recurrences.

Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

There is a wide variety of novel targets and corresponding checkpoint and immune blocker/activator therapies that may soon show promise in cancer care.

Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses the lenvatinib trial.

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).

Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia.

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.

Patience is a virtue when it comes to deciding whether to switch therapies for individuals with metastatic non–small cell lung cancer who appear to be progressing on an EGFR-targeting regimen.

Multiple options currently exist for patients with EGFR-positive non–small cell lung cancer, with additional therapies on the horizon, making upfront treatment selection an increasingly difficult endeavor.

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

Philip J. Buffington, MD, chief medical officer at The Urology Group, discusses administering degarelix (Firmagon) and determining which patients to treat with the hormonal therapy.buffington-thumb.jpg

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer and mesothelioma, which are two aggressive thoracic malignancies with few options.

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.